Literature DB >> 27418206

Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Quinn T Ostrom1,2, Haley Gittleman1,2, Carol Kruchko2, David N Louis3, Daniel J Brat4, Mark R Gilbert5, Valentina I Petkov6, Jill S Barnholtz-Sloan7,8.   

Abstract

Cancer registries are an important source of population-level information on brain tumor incidence and survival. Surveillance, Epidemiology, and End Results (SEER) registries currently collect data on specific required factors related to brain tumors as defined by the American Joint Commission on Cancer, including World Health Organization (WHO) grade, MGMT methylation and 1p/19q codeletion status. We assessed 'completeness', defined as having valid values over the time periods that they have been collected, overall, by year, histology, and registry. Data were obtained through a SEER custom data request for four factors related to brain tumors for the years 2004-2012 (3/4 factors were collected only from 2010 to 2012). SEER*Stat was used to generate frequencies of 'completeness' for each factor overall, and by year, histology and registry. The four factors varied in completeness, but increased over time. WHO grade has been collected the longest, and showed significant increases in completeness. Completeness of MGMT and 1p/19q codeletion was highest for glioma subtypes for which testing is recommended by clinical practice guidelines. Completeness of all factors varied by histology and cancer registry. Overall, several of the factors had high completeness, and all increased in completeness over time. With increasing focus on 'precision medicine' and the incorporation of molecular parameters into the 2016 WHO CNS tumor classification, it is critical that the data are complete, and factors collected at the population level are fully integrated into cancer reporting. It is critical that cancer registries continue to collect established and emerging prognostic and predictive factors.

Entities:  

Keywords:  1p/19q codeletion; Brain tumors; Cancer registration; MGMT methylation; WHO grade

Mesh:

Substances:

Year:  2016        PMID: 27418206      PMCID: PMC5071143          DOI: 10.1007/s11060-016-2217-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study.

Authors:  K Aldape; M L Simmons; R L Davis; R Miike; J Wiencke; G Barger; M Lee; P Chen; M Wrensch
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

2.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.

Authors:  Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-08-21       Impact factor: 17.088

3.  A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Authors:  Martin J van den Bent; Lonneke A Gravendeel; Thierry Gorlia; Johan M Kros; Lariesa Lapre; Pieter Wesseling; Johannes L Teepen; Ahmed Idbaih; Marc Sanson; Peter A E Sillevis Smitt; Pim J French
Journal:  Clin Cancer Res       Date:  2011-09-13       Impact factor: 12.531

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011.

Authors:  Ryan L Lym; Quinn T Ostrom; Carol Kruchko; Marta Couce; Daniel J Brat; David N Louis; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-04-12       Impact factor: 4.130

6.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

Authors:  M Nakamura; T Watanabe; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

7.  Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.

Authors:  Michael A Vogelbaum; Chen Hu; David M Peereboom; David R Macdonald; Caterina Giannini; John H Suh; Robert B Jenkins; Nadia N Laack; David G Brachman; Dennis C Shrieve; Luis Souhami; Minesh P Mehta
Journal:  J Neurooncol       Date:  2015-06-19       Impact factor: 4.130

8.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

Review 10.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

View more
  22 in total

1.  Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014.

Authors:  Haley Gittleman; Alexander Boscia; Quinn T Ostrom; Gabrielle Truitt; Yi Fritz; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

Review 2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

3.  Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients-a Tertiary Experience.

Authors:  Ravindra Pramod Deshpande; Chandrasekhar Y B V K; Manas Panigrahi; Phanithi Prakash Babu
Journal:  Indian J Surg Oncol       Date:  2018-10-30

Review 4.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

5.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-11-06       Impact factor: 12.300

6.  Multimodal assessment of SERS nanoparticle biodistribution post ingestion reveals new potential for clinical translation of Raman imaging.

Authors:  Jos L Campbell; Elliott D SoRelle; Ohad Ilovich; Orly Liba; Michelle L James; Zhen Qiu; Valerie Perez; Carmel T Chan; Adam de la Zerda; Cristina Zavaleta
Journal:  Biomaterials       Date:  2017-04-28       Impact factor: 12.479

Review 7.  Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Authors:  Paul Letendre; Varun Monga; Mohammed Milhem; Yousef Zakharia
Journal:  Future Oncol       Date:  2016-11-24       Impact factor: 3.404

8.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

9.  Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.

Authors:  Adah S Zhang; Quinn T Ostrom; Carol Kruchko; Lisa Rogers; David M Peereboom; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

10.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Authors:  Quinn T Ostrom; David J Cote; Mustafa Ascha; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.